Document is current
Any future updates will be listed below
-
Authors
Parish, Sarah https://orcid.org/0000-0003-3532-0832
Buck, Georgina
Aung, Theingi
Mafham, Marion
Clark, Sarah
Hill, Michael R.
Collins, Rory
Bowman, Louise
Armitage, Jane
,
-
Funding
Funding for this research was provided by:
British Heart Foundation (SP/03/002, SP/08/010/25939, SP/14/3/31114, PG/05/013/18296)
Medical Research Council (MC_UU_00017/3, MC_UU_00017/5)
- License Information
-
More Information
Article History
Received: 30 September 2022
Accepted: 21 February 2023
First Online: 4 March 2023
Declarations
:
: The ASCEND trial was approved by the North West Multicenter Research Ethics Committee and all participants provided written informed consent.
: Not applicable.
: SP, MM, GB, SC, MRH, RC, LB, and JA work in the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) of the Nuffield Department of Population Health at the University of Oxford. The Clinical Trial Service Unit & Epidemiological Studies Unit has a staff policy of not taking any personal payments directly or indirectly from industry (with reimbursement sought only for the costs of travel and accommodation to attend scientific meetings). CTSU has received research grants from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, The Medicines Company, Merck, Mylan, Novartis, Pfizer, Roche, Schering, and Solvay, which are governed by University of Oxford contracts that protect the researchers’ independence. SP and RC are co-inventors of a genetic test for statin-related myopathy risk but receive no income from it.
